Wegovy Outperforms Competitors in Cardiovascular Risk Reduction

Novo Nordisk's Wegovy showed a 57% greater heart attack/stroke/death risk reduction vs. Eli Lilly's GLP-1s (Mounjaro/Zepbound) in overweight/obese patients with cardiovascular disease but no diabetes. This suggests unique heart benefits for semaglutide, potentially increasing insurance coverage.